Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Kazia Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KZA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: KZA's weekly volatility has decreased from 14% to 9% over the past year.
7 Day Return
1 Year Return
Return vs Industry: KZA exceeded the Australian Biotechs industry which returned -7.4% over the past year.
Return vs Market: KZA exceeded the Australian Market which returned 35.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kazia Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWe Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
1 month ago | Simply Wall StWhen Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
2 months ago | Simply Wall StCould The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Is Kazia Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: KZA (A$1.27) is trading below our estimate of fair value (A$15.69)
Significantly Below Fair Value: KZA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: KZA is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: KZA is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KZA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KZA is overvalued based on its PB Ratio (5x) compared to the AU Biotechs industry average (4.7x).
How is Kazia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KZA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: KZA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: KZA's is expected to become profitable in the next 3 years.
Revenue vs Market: KZA's revenue (34.5% per year) is forecast to grow faster than the Australian market (4.9% per year).
High Growth Revenue: KZA's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KZA is forecast to be unprofitable in 3 years.
How has Kazia Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KZA is currently unprofitable.
Growing Profit Margin: KZA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KZA is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.
Accelerating Growth: Unable to compare KZA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (30.3%).
Return on Equity
High ROE: KZA has a negative Return on Equity (-40.88%), as it is currently unprofitable.
How is Kazia Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: KZA's short term assets (A$20.6M) exceed its short term liabilities (A$2.7M).
Long Term Liabilities: KZA's short term assets (A$20.6M) exceed its long term liabilities (A$5.2M).
Debt to Equity History and Analysis
Debt Level: KZA is debt free.
Reducing Debt: KZA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KZA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KZA has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 1.1% each year.
What is Kazia Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KZA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KZA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KZA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KZA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KZA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
James Garner (47 yo)
Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1,...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD734.61K) is above average for companies of similar size in the Australian market ($USD289.08K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Management: KZA's management team is considered experienced (4.7 years average tenure).
Experienced Board: KZA's board of directors are considered experienced (4.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: KZA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37%.
Kazia Therapeutics Limited's company bio, employee growth, exchange listings and data sources
- Name: Kazia Therapeutics Limited
- Ticker: KZA
- Exchange: ASX
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$163.970m
- Shares outstanding: 129.62m
- Website: https://www.kaziatherapeutics.com
- Kazia Therapeutics Limited
- Three International Towers
- Level 24
- New South Wales
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mT...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 08:25|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.